Skip to main content

Table 3 Results of ROC curve analysis and contingency table analysis for NT-proBNP and PFT

From: N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study

Variable Comparison
groups
Optimal cut point Sensitivity
(95% CI)
Specificity
(95% CI)
+LR -LR AUC
NT-proBNP
(ng/ml)
PAH versus control ≥ 209.8 92.9%
(64.1%-99.6%)
100%
(85.9%-99.7%)
- 0.07
(0.01-0.47)
0.93
(0.80-1.0)
  PAH versus ILD ≥ 360.5 85.7%
(56.2%-97.0%)
100.0%
(71.8%-99.5%)
- 0.14
(0.04-0.52)
0.92
(0.78-1.0)
DLCOcorr% PAH versus control < 70.3 100%
(73.2%-99.3%)a
100%
(85.7%-99.7%)a
- - 1.0
  PAH versus ILD Nil - - - - 0.42
(0.22-0.63)
FVC/DLCO PAH versus control ≥ 1.66 64.3%
(35.6%-86.0%)
96.7%
(80.9%-99.8%)
19.3
(2.7- .)
0.37
(0.18-0.75)
0.90
(0.78-1.0)
  PAH versus ILD ≥ 1.82 50.0%
(24.0%-76.0%)
94.4%
(70.6%-99.7%)
9.0
(1.2-64.9)
0.53
(0.31-0.90)
0.71
(0.51-0.90)
DLCO < 70.3%
and
FVC/DLCO
≥ 1.82
PAH versus control - 50.0%
(24.0%-76.0%)
100%
(85.9%-99.7%)
- 0.63
(0.43-0.91)
-
  PAH versus ILD - 50.0%
(24.0%-76.0%)
94.4%
(70.6%-99.7%)
6.75
(0.9-50.2)
0.66
(0.45-0.98)
-
DLCO < 70.3% and
FVC/DLCO ≥ 1.82 (A)
and/or
NT-proBNP ≥ 209.8 (B)
PAH versus control - 100%
(73.2%-99.3%)a
100%
(85.9%-99.7%)a
- - -
  PAH versus ILD - 100%
(73.2%-99.3%)a
77.8%
(51.9%-92.6%)
4.50
(1.90-10.7)
- -
  1. DLCO, diffusing capacity of lungs for carbon monoxide, % predicted; FVC, forced vital capacity, % predicted; ILD, interstitial lung disease; NT-proBNP, N-terminal pro brain natriuretic peptide; PAH, pulmonary arterial hypertension; (A) and (B) refer to the two components of the "composite" screening model. aBecause of the relatively small sample size, the upper limit of the 95% CI approximates but does not equal 100%.